Beranda › Kanker Paru Non-Sel Kecil › Indiana › Hammond
Uji klinis Kanker Paru Non-Sel Kecil di Hammond, IN
11 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Hammond (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Menerima pesertaFase 3
- The Community Hospital, Munster · 1 mi jauhnya
- Women's Diagnostic Center - Munster, Munster · 1 mi jauhnya
- Northwest Oncology LLC, Dyer · 6 mi jauhnya
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- The Community Hospital, Munster · 1 mi jauhnya
- Women's Diagnostic Center - Munster, Munster · 1 mi jauhnya
- Northwest Oncology LLC, Dyer · 6 mi jauhnya
- dan 2 lainnya
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Menerima pesertaFase 3
- Northwest Cancer Centers, P.C., Dyer · 6 mi jauhnya
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Franciscan Health, Munster · 1 mi jauhnya
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Menerima pesertaFase 3
- Northwest Cancer Centers, P.C., Dyer · 6 mi jauhnya
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- Ingalls Family Care Center, Calumet City · 3 mi jauhnya
- UChicago Medicine Ingalls Memorial, Harvey · 8 mi jauhnya
- UChicago Medicine at Ingalls - Flossmoor, Flossmoor · 10 mi jauhnya
- dan 1 lainnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Advocate South Suburban Hospital, Hazel Crest · 10 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Advocate South Suburban Hospital, Hazel Crest · 10 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Advocate South Suburban Hospital, Hazel Crest · 10 mi jauhnya
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Menerima pesertaFase 1/2
- Northwest Cancer Centers, Dyer · 6 mi jauhnya
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Advocate South Suburban Hospital, Hazel Crest · 10 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Hammond
- Kanker Paru10 studi
- Kanker Payudara9 studi
- Gagal Jantung8 studi
- Kanker Ovarium5 studi
- Kanker Kolorektal5 studi
- Tekanan Darah Tinggi4 studi
- Kanker Pankreas4 studi
- Karsinoma Sel Skuamosa Kepala dan Leher4 studi
- Degenerasi Makula4 studi
- Kanker Ginjal (Karsinoma Sel Renal)4 studi
- Kanker Metastatik3 studi
- Kanker (semua jenis)3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.